OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Ipragliflozin Add-on Therapy to a GLP-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes (AGATE): A 52-Week Open-Label Study
Hisamitsu Ishihara, Susumu Yamaguchi, Ikko Nakao, et al.
Diabetes Therapy (2018) Vol. 9, Iss. 4, pp. 1549-1567
Open Access | Times Cited: 13
Hisamitsu Ishihara, Susumu Yamaguchi, Ikko Nakao, et al.
Diabetes Therapy (2018) Vol. 9, Iss. 4, pp. 1549-1567
Open Access | Times Cited: 13
Showing 13 citing articles:
Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)
Pierre Gourdy, Patrice Darmon, François Diévart, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 57
Pierre Gourdy, Patrice Darmon, François Diévart, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 57
MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy
Yingxin Xian, Jianping Weng, Fen Xu
Chinese Medical Journal (2020) Vol. 134, Iss. 1, pp. 8-19
Open Access | Times Cited: 86
Yingxin Xian, Jianping Weng, Fen Xu
Chinese Medical Journal (2020) Vol. 134, Iss. 1, pp. 8-19
Open Access | Times Cited: 86
Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
Yoshio Sumida, Masashi Yoneda, Katsutoshi Tokushige, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 6, pp. 1907-1907
Open Access | Times Cited: 59
Yoshio Sumida, Masashi Yoneda, Katsutoshi Tokushige, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 6, pp. 1907-1907
Open Access | Times Cited: 59
Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes
Taichi Nagahisa, Yoshifumi Saisho
Diabetes Therapy (2019) Vol. 10, Iss. 5, pp. 1733-1752
Open Access | Times Cited: 58
Taichi Nagahisa, Yoshifumi Saisho
Diabetes Therapy (2019) Vol. 10, Iss. 5, pp. 1733-1752
Open Access | Times Cited: 58
Unlocking longevity with GLP-1: A key to turn back the clock?
Vivek P. Chavda, Pankti C. Balar, Dixa A. Vaghela, et al.
Maturitas (2024) Vol. 186, pp. 108028-108028
Closed Access | Times Cited: 8
Vivek P. Chavda, Pankti C. Balar, Dixa A. Vaghela, et al.
Maturitas (2024) Vol. 186, pp. 108028-108028
Closed Access | Times Cited: 8
The efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes or obese adults: a systematic review and meta-analysis
Man Guo, Junling Gu, Fang‐Yuan Teng, et al.
Endocrine (2020) Vol. 67, Iss. 2, pp. 294-304
Closed Access | Times Cited: 39
Man Guo, Junling Gu, Fang‐Yuan Teng, et al.
Endocrine (2020) Vol. 67, Iss. 2, pp. 294-304
Closed Access | Times Cited: 39
Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH
Katharina Luise Hupa‐Breier, Janine Dywicki, Björn Hartleben, et al.
Biomedicines (2021) Vol. 9, Iss. 4, pp. 353-353
Open Access | Times Cited: 30
Katharina Luise Hupa‐Breier, Janine Dywicki, Björn Hartleben, et al.
Biomedicines (2021) Vol. 9, Iss. 4, pp. 353-353
Open Access | Times Cited: 30
Combined Sodium-Glucose-Transporters Inhibitors and Glucagon-Like-Peptide Receptor Agonist Compared With Monotherapy Improves Long-Term Survival: A Real-World Registry
David García‐Vega, Sergio Cinza‐Sanjurjo, Sonia Eirás, et al.
The American Journal of Medicine (2024) Vol. 137, Iss. 8, pp. 761-769.e1
Closed Access | Times Cited: 4
David García‐Vega, Sergio Cinza‐Sanjurjo, Sonia Eirás, et al.
The American Journal of Medicine (2024) Vol. 137, Iss. 8, pp. 761-769.e1
Closed Access | Times Cited: 4
Early combination therapy with SGLT2i and GLP ‐1 RA or dual GIP /GLP ‐1 RA in type 2 diabetes
Catarina Vale, Inês Mariana Lourenço, Gabriela Jordan, et al.
Diabetes Obesity and Metabolism (2024) Vol. 27, Iss. 2, pp. 468-481
Closed Access | Times Cited: 4
Catarina Vale, Inês Mariana Lourenço, Gabriela Jordan, et al.
Diabetes Obesity and Metabolism (2024) Vol. 27, Iss. 2, pp. 468-481
Closed Access | Times Cited: 4
Targeting Diabetic Atherosclerosis: The Role of GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Nonsteroidal Mineralocorticoid Receptor Antagonists in Vascular Protection and Disease Modulation
Merita Rroji, Nereida Spahia, Andreja Figurek, et al.
Biomedicines (2025) Vol. 13, Iss. 3, pp. 728-728
Open Access
Merita Rroji, Nereida Spahia, Andreja Figurek, et al.
Biomedicines (2025) Vol. 13, Iss. 3, pp. 728-728
Open Access
Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Scoping Review and Expert Insights for Clinical Practice Utilizing the Nominal Group Technique
Carlos Augusto Yepes, Isabel C. Cardenas-Moreno, Rodrigo Daza-Arnedo, et al.
Diabetes Therapy (2025)
Open Access
Carlos Augusto Yepes, Isabel C. Cardenas-Moreno, Rodrigo Daza-Arnedo, et al.
Diabetes Therapy (2025)
Open Access
Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages
Masao Koike, Hitoki Saito, Genta Kohno, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 21, pp. 11463-11463
Open Access | Times Cited: 7
Masao Koike, Hitoki Saito, Genta Kohno, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 21, pp. 11463-11463
Open Access | Times Cited: 7
Open-Label Study to Assess the Efficacy of Ipragliflozin for Reducing Insulin Dose in Patients with Type 2 Diabetes Mellitus Receiving Insulin Therapy
Hisamitsu Ishihara, Susumu Yamaguchi, Toshifumi Sugitani, et al.
Clinical Drug Investigation (2019) Vol. 39, Iss. 12, pp. 1213-1221
Open Access | Times Cited: 5
Hisamitsu Ishihara, Susumu Yamaguchi, Toshifumi Sugitani, et al.
Clinical Drug Investigation (2019) Vol. 39, Iss. 12, pp. 1213-1221
Open Access | Times Cited: 5
